BOCOM INTL: Raises AKESO (09926) target price to 92 Hong Kong dollars, and Ivosy will usher in several key developments.

BOCOM INTL released a research report stating that AKESO (09926) experienced strong sales growth in the previous year. The bank expects that the group's medical insurance coverage will drive further sales volume this year and achieve a breakeven point. With the overseas registration research of IVOXI entering the sprint stage, more new antibodies, ADCs, and candidates in the self-immunization field entering clinical development, the company's pipeline value continues to increase, raising the target price to HK$92 with a "buy" rating. AKESO's performance exceeded expectations last year and in the second half of the year, with the possibility of recording positive year-on-year net profit by the end of this year in terms of accounting net profit and non-IFRS net profit. Additionally, the bank currently expects the company to record accounting net profit of HK$23 million and non-IFRS net profit of HK$103 million by the end of this year, while also raising the adjusted profit forecast for 2026 by 3% to HK$1.2 billion.